邀请伦贝克首席执行官/首席财务官下周四- 2025年与高管层对话

Event DescriptionAs part of our 2025 European Healthcare C-Suite call series, we are hosting Q&A sessionswith leadership from companies and key opinion leaders in the industry. Investors arewelcome to submit questions in advance (feel free to email) or participate in Q&A duringthe calls (current schedule below). Following each call, we will provide key takeaways aswell as replays/transcripts.Please click on the registration link to express your interest for any of the events. Onceconfirmed, eligible investors will then be provided with the meeting link to access the callahead of the scheduled start time.Speaker BiosCharl van Zyljoined Lundbeck as President & CEO in September 2023. He brings morethan 23 years of experience from commercial international management roles within thepharmaceutical industry, most recently in the fields of immunology and neurology fromUCB where he served as Executive Vice President (EVP) and Head of Neurology globally,responsible for corporate activities in Europe and international markets. He also worked asEVP at BSN Medical, Corporate VP & Commercial Leader EMEA at Bausch & Lomb, CEO atJADO Technologies, Head of Marketing and Sales at Novartis and Business Unit Manager atEli Lilly. Charl is British and holds a degree in Medical Biochemistry from the University ofCape Town, South Africa.Joerg Hornsteinstarted his career with Merck KGaA, where he spent 12 years in financialroles of increasing responsibility acrossdifferentbusinesses, including roles at theHeadquarters in Germany, as well as in Indonesia, China and the USA. Before joiningLundbeck in August 2022, Joerg was with AC Immune SA as EVP and CFO since 2017, wherehe oversaw Finance and various corporate functions. Prior to AC Immune, he served as SVPand Head of Group Controlling for Unternehmensgruppe Theo Mueller. He holds aBachelor of Business Administration from Baylor University – Hankamer School ofBusiness, Texas, US and an MBA with Distinction from London Business School, UK.Relevant Research•H Lundbeck A/S:1Q25 model update; Strategic brand growth highlights valuation•opportunity(15/05/25)•H Lundbeck A/S:1Q25 results; Strong Sales/EBITDA beat drive FY25 Guidance•upgrades(14/05/25)•EU Pharma: Field & Pitman'sTariffToolkit and scenario analysis; AZN/ROG/GRF appear•most protected (10/04/25)Current Schedule (UKT) Register here•28th February, 15:00 - Galapagos - Thad Huston, CFO & COO••7th March, 14:00 - Coloplast - Kristian Villumsen, CEO••24th March, 15:00 - Philips - Charlotte Hanneman, CFO••28th March, 15:00 - Recordati - Luigi La Corte, CFO••7th April, 15:00 - Genmab - Judith Klimovsky, Chief DevelopmentOfficer• •23rd April, 14:00 - Elekta - Tobias Hägglöv, CFO••29th April, 14:00 - UCB - Emmanuel Caemayex, CCO••7th May, 15:00 - Novartis - Harry Kirsch, CFO••12th May, 15:00 - Lonza Group - Philippe Deecke, CFO••19th May, 14:00 - Vimian - Patrik Eriksson, CEO••21st May, 14:00 - GN Store Nord - Peter Karlstromer, CEO••23rd May, 13:30 - Demant - René Schneider, CFO••27th May, 15:00 - Getinge - Mattias Perjos, CEO••28th May, 15:00 - Spire Healthcare - Harbant Samra, CFO••4th June, 15:00 - ConvaTec - Karim Bitar, CEO••10th June, 15:00 - Roche - Matt Sause, CEO Roche Diagnostics••12th June, 14:15 - H Lundbeck - Charl Van Zyl, CEO and Joerg Hornstein, CFO••18th June, 15:00 – Ambu – Britt Meelby Jensen, CEO••19th June, 16:00 - Sectra - Torbjörn Kronander, CEO••23rd June, 14:00 - Fresenius Medical Care - Helen Giza, CEO••27th June, 15:00 - Bayer - Stefan Oelrich, Head of the Pharmaceuticals Division••30th June, 15:00 - Straumann - Yang Xu, CFO••1st July, 16:00 - GSK - Luke Miels, Chief CommercialOfficer••2nd July, 15:00 - Sonova - Arnd Kaldowski, CEO••22nd July, 14:00 - Fresenius SE - Michael Sen, CEO••23rd July, 15:00 - Carl Zeiss Meditec- Justus Wehmer, CFO••8th October, 15:00 - Oxford Nanopore - Gordon Sanghera, CEO, Nick Keher, CFO• Charles Pitman-King,CFA+44 (0)20 3134 6023Barclays, UKMeet the AnalystsEuropean Pharmaceuticals & Life SciencesThis event is intended for Barclays institutional investor clients only. This event is strictly and solelyfor the benefit of the intended recipients. Please do not forward this invitation to any other partywithout written consent from Barclays Research. Barclays' Investment Bankers are prohibited fromattending this event. Participant comments are not for attribution.If your firm is in-scope for research unbundling under MiFID II and you require further informationregarding pricing to participate in this Barclays Research content event, please contact your salesrepresentative.Barclays Capital Inc. and/or one of itsaffiliatesdoes and seeks to do business with companies coveredin its research reports. As a result, investors should be aware that the firm may have a conflict ofinterest that couldaffectthe objectivity of this report. Investors should consider this report as only asingle factor in making their investment decision.Any views or opinions by Barclays research analysts have been